云顶新耀-B(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01952 云顶新耀-B

休市中 09-13 16:08:05

23.500

+0.600

+2.62%

最高23.950	最低22.600	成交量291.82万
今开23.150	昨收22.900	日振幅5.90%
总市值76.43亿	流通市值76.43亿	总股本3.25亿
成交额6,847万	换手率0.90%	流通股本3.25亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀-B","latestPrice":23.5,"timestamp":1726214885015,"preClose":22.9,"halted":0,"volume":2918168,"delay":0,"floatShares":325252818,"shares":325252818,"eps":-2.9634058,"marketStatus":"休市中","marketStatusCode":7,"change":0.6,"latestTime":"09-13 16:08:05","open":23.15,"high":23.95,"low":22.6,"amount":68468063,"amplitude":0.058952,"askPrice":23.6,"askSize":3000,"bidPrice":23.5,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-3.593133523167755,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1726450200000},"adr":0,"listingDate":1602172800000,"adjPreClose":22.9,"openAndCloseTimeList":[[1726191000000,1726200000000],[1726203600000,1726214400000]],"volumeRatio":1.1676521515613265,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952","defaultTab":"news","newsList":[{"id":"1150412802","title":"异动解读 | 云顶新耀-B业绩向好 股价大涨7.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150412802","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150412802?lang=zh_cn&edition=full","pubTime":"2024-09-05 14:48","pubTimestamp":1725518906,"startTime":"0","endTime":"0","summary":"药企云顶新耀-B股价今日大涨7.52%,引发市场关注。据悉,公司此前发布的2024年中期业绩报告表现亮眼,很好解释了股价上涨背后的原因。在最新公布的半年报中,云顶新耀上半年总收入达人民币3.02亿元,较上一年同期大幅增长158%。展望未来,云顶新耀管理层表示,预计到2024年底将有三款产品实现商业化上市,对实现全年人民币7亿元销售目标充满信心,并有望在2025年底前实现现金流盈亏平衡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"gpt_icon":0},{"id":"2465513036","title":"港股异动 | 云顶新耀-B(01952)涨超7% 上半年收入环比大增158% 料年底将有3款产品商业化上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2465513036","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465513036?lang=zh_cn&edition=full","pubTime":"2024-09-05 14:38","pubTimestamp":1725518322,"startTime":"0","endTime":"0","summary":"消息面上，云顶新耀2024年中期业绩显示，公司上半年总收入达人民币3.02亿元，较2023年下半年大幅增长158%，运营费用占收入比重大幅减少249%, 体现了运营效率的显著提升；非国际财务准则亏损显著收窄35%；剔除非现金项目后毛利率为83%，实现公司历史上的首次商业化层面盈利。公司表示，预计到2024年底，公司将有三款产品实现商业化上市。对实现全年人民币7亿元的销售目标非常有信心，并力争在2025年底前实现现金盈亏平衡的战略目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1179676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01952","BK1583","BK1161"],"gpt_icon":0},{"id":"2465561999","title":"云顶新耀-B(01952)上涨5.01%，报23.05元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2465561999","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465561999?lang=zh_cn&edition=full","pubTime":"2024-09-05 10:02","pubTimestamp":1725501743,"startTime":"0","endTime":"0","summary":"9月5日，云顶新耀-B(01952)盘中上涨5.01%，截至10:02，报23.05元/股，成交2180.33万元。云顶新耀有限公司是一家专门从事创新药和疫苗的研发、临床开发、制造和商业化的生物制药公司，主要服务大中华区和其他亚洲市场。公司在药物和疫苗的自主研发上表现优异，同时在肾科疾病、mRNA平台、感染性和传染性疾病、自身免疫性疾病等领域已建立全球同类首创或者同类最佳的药物和疫苗组合。截至2024年中报，云顶新耀-B营业总收入3.02亿元、净利润-6.32亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/09/05100243045858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","01952","BK1161","BK1583"],"gpt_icon":0},{"id":"1169593302","title":"异动解读 | 云顶新耀上半年业绩增长强劲 两大主导产品销售放量 股价盘中大涨7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1169593302","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169593302?lang=zh_cn&edition=full","pubTime":"2024-09-02 13:56","pubTimestamp":1725256586,"startTime":"0","endTime":"0","summary":"云顶新耀-B(01952)股价今日盘中大涨7%,引发市场关注。消息面上,该公司今年上半年业绩取得大幅增长,收益同比飙升3289.74%至3.02亿元人民币,主要得益于旗下两大主打产品依嘉和耐赋康销售实现大增长。\n\n其中,医药产品依嘉销售额环比增长35%至1.34亿元,在中国多个省市持续扩大覆盖。研究显示,依嘉获纳入多项临床指南,加上覆盖市场不断深化,未来销售有望继续保持增长态势。\n\n另一产品耐赋康今年5月在国内上市后,仅一个半月销售额就达1.67亿元,增长潜力十分可观。据悉,该产品已向NMPA申请完全批准,如果明年上半年获批,预计将进一步推动销售增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"gpt_icon":0},{"id":"2464088650","title":"港股异动 | 云顶新耀-B(01952)午后涨超7% 依嘉和耐赋康销售明显放量 上半年产品销售环比增超1.5倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2464088650","media":"智通财经网","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464088650?lang=zh_cn&edition=full","pubTime":"2024-09-02 13:49","pubTimestamp":1725256194,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀-B午后涨超7%，截至发稿，涨6.76%，报22.1港元，成交额5443.35万港元。消息面上，云顶新耀此前发布中期业绩，该集团取得收益人民币3.02亿元，同比增长3289.74%。公告称，收益增加主要是由于依嘉在中国大陆及中国香港持续扩大销售、耐赋康在中国大陆及新加坡上市以及耐赋康在我们许可的其他地区销售的综合影响。交银国际发布研报称，云顶新耀上半年新品销售表现优异，产品销售环比大增158%至3.02亿元人民币，高于市场预期。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1177881.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","01952","BK1574","BK1583"],"gpt_icon":0},{"id":"2464707900","title":"云顶新耀-B(01952)上涨5.07%，报21.75元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2464707900","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464707900?lang=zh_cn&edition=full","pubTime":"2024-09-02 13:39","pubTimestamp":1725255580,"startTime":"0","endTime":"0","summary":"9月2日，云顶新耀-B(01952)盘中上涨5.07%，截至13:39，报21.75元/股，成交4193.82万元。云顶新耀有限公司是一家专门从事创新药和疫苗的研发、临床开发、制造和商业化的生物制药公司，主要服务大中华区和其他亚洲市场。公司在药物和疫苗的自主研发上表现优异，同时在肾科疾病、mRNA平台、感染性和传染性疾病、自身免疫性疾病等领域已建立全球同类首创或者同类最佳的药物和疫苗组合。截至2024年中报，云顶新耀-B营业总收入3.02亿元、净利润-6.32亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/09/02133942959010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1161","01952","BK1574"],"gpt_icon":0},{"id":"2464085250","title":"云顶新耀－Ｂ(01952)股价上升5.072%，现价港币$21.75","url":"https://stock-news.laohu8.com/highlight/detail?id=2464085250","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464085250?lang=zh_cn&edition=full","pubTime":"2024-09-02 13:39","pubTimestamp":1725255540,"startTime":"0","endTime":"0","summary":"[上升股]云顶新耀－Ｂ(01952) 股价在下午01:39比前收市价上升5.072%，现股价为港币$21.75。至目前为止，今日最高价为$21.75，而最低价为$20.75。总成交量为196.98万股，总成交金额为港币$4.193千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2409021789/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1583","BK1161","01952"],"gpt_icon":1},{"id":"2463974234","title":"云顶新耀引爆效率革命","url":"https://stock-news.laohu8.com/highlight/detail?id=2463974234","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463974234?lang=zh_cn&edition=full","pubTime":"2024-08-31 11:34","pubTimestamp":1725075257,"startTime":"0","endTime":"0","summary":"在行业低谷期，市场迫切需要一场效率革命：即在最短的时间内、用最高效投入，创造出最大的价值。云顶新耀就是这样一个典型例子。显然，云顶新耀在达成这一目标上已经迈出了坚实的步伐，距离盈亏平衡点越来越近。虽然云顶新耀并非“效率革命”的发起者，但它正在推动这场革命走向更加激烈的阶段。然而，云顶新耀却能够取得“最大的成就”，在18A企业中独树一帜。云顶新耀不仅能推动多款产品上市，还能实现产品上市即快速放量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/239229","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1161","BK1583","01952","BK1574"],"gpt_icon":0},{"id":"2463779782","title":"云顶新耀上半年总收入3.02亿元 首次实现商业化层面盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2463779782","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463779782?lang=zh_cn&edition=full","pubTime":"2024-08-30 14:27","pubTimestamp":1724999235,"startTime":"0","endTime":"0","summary":"8月28日，云顶新耀发布2024年中期业绩报告。上半年，云顶新耀总收入3.02亿元；毛利2.31亿元，剔除非现金项目后毛利率为83%，首次实现商业化层面盈利。截至2024年上半年，云顶新耀现金储备为19.3亿元。分产品来看，云顶新耀的收入构成主要由肾科药物耐赋康、抗菌药物依嘉构成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202408303171433494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1583","BK1161","01952"],"gpt_icon":0},{"id":"2463281107","title":"云顶新耀-B(01952)1H24产品销售放量超预期，下一波创新药上市潮将至，上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2463281107","media":"交银国际","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463281107?lang=zh_cn&edition=full","pubTime":"2024-08-29 17:14","pubTimestamp":1724922852,"startTime":"0","endTime":"0","summary":"1H24依嘉和耐赋康销售放量显著且超预期，我们上调2024-25年收入预测、上调目标价至44.0港元。未来18个月内催化剂丰富，维持买入评级。公司在耐赋康的商业化模式非常高效精干，在纳入医保前仅用120名销售代表覆盖了500家大型三甲医院，代表了全国60%的市场潜力，1H24销售费用率显著下降、人效显著提升，同时和CSO合作覆盖外围市场。截至1H24末的账上现金为19.3亿元，公司维持2024年产品销售收入7亿元、2025年实现现金流层面盈亏平衡的指引。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082917310695cf6ec7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082917310695cf6ec7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","01952"],"gpt_icon":0},{"id":"2463007684","title":"云顶新耀-B08月29日遭主力抛售170万元 环比增加335.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463007684","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463007684?lang=zh_cn&edition=full","pubTime":"2024-08-29 16:16","pubTimestamp":1724919371,"startTime":"0","endTime":"0","summary":"08月29日, 云顶新耀-B股价跌3.10%，报收20.30元，成交金额5936万元，换手率0.89%，振幅5.25%，量比1.02。云顶新耀-B今日主力资金净流出170万元，上一交易日主力净流出39万元，今日环比增加335.90%。该股近5个交易日上涨4.75%，主力资金累计净流入787万元；近20日主力资金累计净流入466万元，其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082916173195cf29a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082916173195cf29a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","BK1161","01952"],"gpt_icon":0},{"id":"2463409538","title":"【券商聚焦】交银国际升云顶新耀(01952)目标价7.32% 指依嘉和耐赋康销售放量显著且超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2463409538","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463409538?lang=zh_cn&edition=full","pubTime":"2024-08-29 15:05","pubTimestamp":1724915117,"startTime":"0","endTime":"0","summary":"截至1H24末的账上现金为19.3亿元，公司维持2024年产品销售收入7亿元、2025年实现现金流层面盈亏平衡的指引。该行表示，1H24依嘉和耐赋康销售放量显著且超预期，该行上调2024-25年收入预测、上调目标价，由41港元升至44港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408291506059f6475bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408291506059f6475bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01952"],"gpt_icon":0},{"id":"2462554514","title":"云顶新耀-B(01952)：规模商业化价值再获业绩验证，双轮驱动持续拉升价值曲线","url":"https://stock-news.laohu8.com/highlight/detail?id=2462554514","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462554514?lang=zh_cn&edition=full","pubTime":"2024-08-28 19:14","pubTimestamp":1724843664,"startTime":"0","endTime":"0","summary":"8月27日，云顶新耀-B(01952)2024年中报业绩新鲜出炉。财报显示，公司当期营业收入达到3.02亿元(人民币，单位下同)，同比大幅增长3289.74%。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20240828/20240828191435_81106.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240828/20240828191435_81106.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1173507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","01952","BK1583","BK1574"],"gpt_icon":0},{"id":"2462106971","title":"云顶新耀2024年半年报：收入达3.02亿元 首次实现商业化层面盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2462106971","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462106971?lang=zh_cn&edition=full","pubTime":"2024-08-28 12:19","pubTimestamp":1724818744,"startTime":"0","endTime":"0","summary":"报告显示，2024年上半年总收入达到人民币3.02亿元，较2023年下半年大幅增长158%，并实现公司历史上的首次商业化层面盈利。此外，作为云顶新耀首款商业化上市的产品，全球首个氟环素类抗菌药物依嘉已经完成首个完整销售年度，增长势头强劲，今年上半年收入达到1.342亿元，依嘉自2023年7月商业化以来已经实现了人民币2.33亿元收入。云顶新耀预计将于2024年下半年公布EVER001在膜性肾病的1b期临床研究顶线结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408281219079f605b56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408281219079f605b56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01952","BK1583","BK1161"],"gpt_icon":0},{"id":"2462757061","title":"云顶新耀-B绩后涨逾7% 上半年收益3.02亿元同比大增3289.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462757061","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462757061?lang=zh_cn&edition=full","pubTime":"2024-08-28 09:40","pubTimestamp":1724809211,"startTime":"0","endTime":"0","summary":"云顶新耀-B（01952）绩后上涨6.91%，现报22.45港元，成交额3552.47万港元。\n　　云顶新耀-B发布截至2024年6月30日止6个月中期业绩，该集团取得收益人民币3.02亿元（单位下同），同比增长3289.74%；研发开支2.53亿元，同比减少12.25%；公司拥有人应占亏损6.32亿元，每股亏损1.97元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-28/doc-incmczxq5295222.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-28/doc-incmczxq5295222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1574","BK1583","BK1161","01952"],"gpt_icon":0},{"id":"1127457668","title":"异动解读 | 云顶新耀上半年收益飙升三成 但亏损扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=1127457668","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127457668?lang=zh_cn&edition=full","pubTime":"2024-08-28 09:37","pubTimestamp":1724809050,"startTime":"0","endTime":"0","summary":"生物科技公司云顶新耀有限公司今日公布2024年上半年中期业绩。尽管录得亏损,但收益呈现强劲增长势头,令投资者对公司前景重燃信心,公司股价今日盘中一度大涨逾6%。报告期内,云顶新耀实现收益约3.015亿元人民币,同比大增3289.74%,主要是由于旗舰产品依嘉和耐赋康在中国大陆、香港以及新加坡等地区持续扩大销售所致。展望未来,云顶新耀计划于2024年下半年在韩国获得耐赋康上市许可,并有望在香港实现同款产品的商业化上市。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"gpt_icon":0},{"id":"2462176092","title":"《业绩》云顶新耀(01952.HK)半年亏损扩大至6.32亿人币","url":"https://stock-news.laohu8.com/highlight/detail?id=2462176092","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462176092?lang=zh_cn&edition=full","pubTime":"2024-08-28 09:35","pubTimestamp":1724808900,"startTime":"0","endTime":"0","summary":"云顶新耀-B公布截至今年6月底止中期业绩，营业额3.02亿元人民币(下同)，按年升3,289.7%。亏损扩大至6.32亿元，上年同期蚀4.24亿元；每股亏损1.97元。过往派息公布日期派息事项派息内容2024/03/28末期业绩无派息2023/08/24中期业绩无派息2023/03/31末期业绩无派息 2022/08/24中期业绩无派息 期内，非国际财务报告准则计量的经调整亏损按年收窄至2.13亿元，去年同期亏损3.27亿元。云顶新耀今日高开4.3%报21.9元，现报22.7元，升8.1%，成交152.93万股，涉资3,399.16万元。沽空资料截至 2024-08-27 16:25。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210311103606358_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210311103606358_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1376041/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1583","01952","BK1574"],"gpt_icon":0},{"id":"2462139175","title":"港股异动 | 云顶新耀-B(01952)绩后涨超5% 上半年收益3.02亿元 同比大幅增长3289.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462139175","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462139175?lang=zh_cn&edition=full","pubTime":"2024-08-28 09:32","pubTimestamp":1724808765,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀-B(01952)绩后涨超5%，截至发稿，涨5.48%，报22港元，成交额1497.48万港元。消息面上，云顶新耀-B发布截至2024年6月30日止6个月中期业绩，该集团取得收益人民币3.02亿元(单位下同)，同比增长3289.74%;研发开支2.53亿元，同比减少12.25%;公司拥有人应占亏损6.32亿元，每股亏损1.97元。公告称，收益增加主要是由于依嘉在中国大陆及中国香港持续扩大销售、耐赋康在中国大陆及新加坡上市以及耐赋康在我们许可的其他地区销售的综合影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1172802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1583","BK1161","01952"],"gpt_icon":0},{"id":"2462617682","title":"云顶新耀－Ｂ(01952)股价上升5%，现价港币$22.05","url":"https://stock-news.laohu8.com/highlight/detail?id=2462617682","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462617682?lang=zh_cn&edition=full","pubTime":"2024-08-28 09:30","pubTimestamp":1724808600,"startTime":"0","endTime":"0","summary":"[上升股]云顶新耀－Ｂ(01952) 股价在上午09:30比前收市价上升5%，现股价为港币$22.05。至目前为止，今日最高价为$22.05，而最低价为$21.5。总成交量为19.45万股，总成交金额为港币$425.278万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR24082824/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","01952","BK1583","BK1574"],"gpt_icon":0},{"id":"2462173611","title":"【港股通】云顶新耀(01952)中期亏损扩大至6.32亿元人民币 不派息","url":"https://stock-news.laohu8.com/highlight/detail?id=2462173611","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462173611?lang=zh_cn&edition=full","pubTime":"2024-08-28 09:16","pubTimestamp":1724807818,"startTime":"0","endTime":"0","summary":"金吾财讯 | 云顶新耀 公告，截至2024年6月30日止六个月，公司权益持有人应占期内亏损录得6.32亿元，同比增长49.29%。主要由于与mRNACOVID-19疫苗有关的无形资产的一次性、非经常性减值亏损。每股基本亏损1.97元，不派息。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200915/M2I0MjRmYjFhYTkyMTQ4NzQ4YmZjZmNiNjI1MDU4NTA0Mw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/M2I0MjRmYjFhYTkyMTQ4NzQ4YmZjZmNiNjI1MDU4NTA0Mw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1943157","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSTECH","HSCEI","BK1161","01952","07226","BK1583","BK1574","YANG"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.2317},{"period":"3month","weight":0.1605},{"period":"6month","weight":-0.082},{"period":"1year","weight":0.3663},{"period":"ytd","weight":0.1244}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":0.0149},{"period":"3month","weight":-0.0319},{"period":"6month","weight":0.0388},{"period":"1year","weight":-0.0376},{"period":"ytd","weight":0.0189}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"云顶新耀有限公司是一家主要从事疗法的特许、临床开发及商业化业务，以解决尚未满足的医疗需求。该公司一直专注于创新候选药物的研发。该公司已开发极具前景的临床阶段候选药物产品组合，覆盖肿瘤、免疫学、心肾疾病及感染性疾病。该公司主要在大中华及亚太区其他新兴市场提供产品与服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.043978},{"month":2,"riseRate":0.25,"avgChangeRate":0.025861},{"month":3,"riseRate":0.25,"avgChangeRate":-0.030941},{"month":4,"riseRate":0.25,"avgChangeRate":-0.098869},{"month":5,"riseRate":0.5,"avgChangeRate":-0.010924},{"month":6,"riseRate":0.75,"avgChangeRate":0.281644},{"month":7,"riseRate":0,"avgChangeRate":-0.15054},{"month":8,"riseRate":0.25,"avgChangeRate":-0.139716},{"month":9,"riseRate":0.75,"avgChangeRate":0.042143},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.050127},{"month":11,"riseRate":0.5,"avgChangeRate":0.116383},{"month":12,"riseRate":0.75,"avgChangeRate":0.148847}],"exchange":"SEHK","name":"云顶新耀-B","nameEN":"EVEREST MED - B"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀-B(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀-B(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀-B,01952,云顶新耀-B股票,云顶新耀-B股票老虎,云顶新耀-B股票老虎国际,云顶新耀-B行情,云顶新耀-B股票行情,云顶新耀-B股价,云顶新耀-B股市,云顶新耀-B股票价格,云顶新耀-B股票交易,云顶新耀-B股票购买,云顶新耀-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀-B(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀-B(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}